SOLVENTUM CORP
SOLVNYSETrading Snapshot
- Day Range
- $81.38 – $83.33
- 52-Week Range
- $62.38 – $94.16
- Volume (shares)
- 1,564,639
- Avg Volume (shares)
- —
- Shares Outstanding
- 170.2M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $8.32B
- Last Q Revenue
- $2.21B
- P/E Ratio
- 10.0
- P/S Ratio
- 1.7x
- EPS (TTM)
- $8.27
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.5%
SOLVENTUM CORP
SOLV
StockOtter · stockotter.spaceAbout SOLVENTUM CORP
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
SOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH) plans to report third quarter 2026 results on Thursday, November 12, 2026. Management will present results during a c
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic electrospun fiber matri
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.